Assess whether scientific advice should be sought before the next trial

SITUATION A pediatric ethicist objecting to the proposed design put inspection-readiness findings at a CMO in front of CMC change-control owner in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / Clinical and Evidence Strategy close is scientific advice should be from inspection-readiness findings at a CMO, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after a pediatric ethicist objecting to the proposed design. 2. Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after a pediatric ethicist objecting to the proposed design for CMC change-control owner. 3. Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision scientific advice should be turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in inspection-readiness findings at a CMO, then the action for CMC change-control owner - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in inspection-readiness findings at a CMO that a second reviewer can re-perform